Investor Call Rescheduled to Tuesday, Feb. 8
at 8:30 a.m. EST to Discuss Combination between Comera Life
Sciences, Inc. and OTR Acquisition Corp.
OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW), a
publicly traded special purpose acquisition company (SPAC), today
announced the confidential submission with the U.S. Securities and
Exchange Commission (“SEC”) of a draft registration statement on
Form S-4 (the “Registration Statement”) relating to its previously
announced proposed business combination with Comera Life Sciences,
Inc.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220203006027/en/
In addition, the investor call with Comera and OTR has been
rescheduled to Tuesday, Feb. 8 at 8:30 a.m. EST (from previous date
and time of Friday, Feb. 4 at 8:30 a.m. EST) to discuss the
proposed business combination. An audio webcast of the event will
be available on the OTR Investor Relations website at
https://otracquisition.com/investors/.
About OTR Acquisition Corp.
OTR Acquisition Corp. (Nasdaq: OTRA) is a $107 million special
purpose acquisition company formed for the purpose of effecting a
merger, capital stock exchange, asset acquisition, stock purchase,
reorganization or similar business combination with one or more
businesses. OTR is sponsored by OTR Acquisition Sponsor LLC, an
affiliate of investor and entrepreneur Nicholas J. Singer and
Purchase Capital. OTR’s units, Class A common stock and warrants
trade on the Nasdaq Stock Market LLC (“Nasdaq”) under the ticker
symbols “OTRAU,” “OTRA,” and “OTRAW,” respectively.
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life
Sciences is applying a deep knowledge of formulation science and
technology to transform essential biologic medicines from
intravenous (IV) to subcutaneous (SQ) forms. The goal of this
approach is to provide patients with the freedom of self-injectable
care, reduce institutional dependency and to put patients at the
center of their treatment regimen.
To learn more about the Comera Life Sciences mission, as well as
the proprietary SQore™ platform, visit
https://comeralifesciences.com/.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws with respect to
the proposed business combination between OTR and Comera. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including, but not
limited to: (i) the risk that the transaction may not be completed
in a timely manner or at all, which may adversely affect the price
of OTR’s securities, (ii) the risk that the transaction may not be
completed by OTR’s business combination deadline and the potential
failure to obtain an extension of the business combination deadline
if sought by OTR, (iii) the failure to satisfy the conditions to
the consummation of the transaction, including the adoption of the
business combination agreement by the stockholders of OTR, the
satisfaction of the minimum trust account amount following
redemptions by OTR’s public stockholders, and (iv) the risk that
the post-combination company’s securities will not be approved for
listing on Nasdaq or if approved, maintain the listing. The
foregoing list of factors is not exhaustive. Readers are cautioned
not to put undue reliance on forward-looking statements, and no
party assumes any obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise nor do they give any assurance that
either Comera nor OTR will achieve its expectations.
Important Information About the Proposed Business Combination
and Where to Find It
In connection with the proposed business combination, Comera
Life Sciences Holdings, Inc. (“Holdco”) will file the Registration
Statement publicly which will include a proxy statement of OTR and
a prospectus of Holdco. The definitive proxy statement/prospectus
will be sent to all OTR and Comera stockholders. Holdco and OTR
will also file other documents regarding the proposed business
combination with the SEC. Before making any voting decision,
investors and securities holders of OTR and Comera are urged to
read the proxy statement/prospectus and all other relevant
documents filed or that will be filed with the SEC in connection
with the proposed business combination as they become available
because they will contain important information about the proposed
business combination and the parties to the proposed business
combination.
Investors and securities holders will be able to obtain free
copies of the proxy statement/prospectus and all other relevant
documents filed or that will be filed with the SEC by Holdco
through the website maintained by the SEC at https://sec.gov/. In
addition, the documents filed by OTR may be obtained free of charge
from OTR’s website at https://otracquisition.com/investors/ or by
written request to OTR Acquisition Corp., 1395 Brickell Avenue,
Suite 800, Miami, Florida 33131.
Participants in the Solicitation
Holdco, OTR and Comera and their respective directors and
officers may be deemed to be participants in the solicitation of
proxies from OTR’s stockholders in connection with the proposed
business combination. Information about OTR’s directors and
executive officers and their ownership of OTR’s securities is set
forth in OTR’s filings with the SEC, including OTR’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2020, which was
filed with the SEC on March 3, 2021 as amended on December 13,
2021. To the extent that holdings of OTR’s securities have changed
since the amounts printed in OTR’s Annual Report, such changes have
been or will be reflected on Statements of Change in Ownership on
Form 4 filed with the SEC. Additional information regarding the
interests of those persons and other persons who may be deemed
participants in the proposed business combination may be obtained
by reading the proxy statement/prospectus regarding the proposed
business combination when it becomes available. You may obtain free
copies of these documents as described in the preceding
paragraph.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
No offering of securities shall be made except by means of a
prospectus meeting the requirements of Section 10 of the Securities
Act.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220203006027/en/
OTR Contact Melanie Gounardes Prosek Partners
Mgounardes@prosek.com
Investor Contact John Woolford ICR Westwicke
John.Woolford@westwicke.com
Comera Press Contact Sean Leous ICR Westwicke
Sean.Leous@westwicke.com
OTR Acquisition (NASDAQ:OTRAU)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
OTR Acquisition (NASDAQ:OTRAU)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024